---
title: "VolitionRx Limited (VNRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VNRX.US.md"
symbol: "VNRX.US"
name: "VolitionRx Limited"
industry: "Health Care Supplies"
datetime: "2026-05-21T23:18:36.385Z"
locales:
  - [en](https://longbridge.com/en/quote/VNRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VNRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VNRX.US.md)
---

# VolitionRx Limited (VNRX.US)

## Company Overview

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

| Item | Detail |
|------|--------|
| Industry | Health Care Supplies |
| Exchange | US Market |
| Website | [volition.com](https://volition.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: C (0.49)**

**Industry**: Health Care Supplies

| Metric | Value |
|--------|-------|
| Industry Ranking | 30 / 45 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 88.49% |  |
| Net Profit YoY | -2.39% |  |
| P/B Ratio | -0.62 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 19730914.38 |  |
| Revenue | 2466075.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 82.34% | A |
| Profit Margin | -997.46% | E |
| Gross Margin | 54.30% | B |
| Revenue YoY | 88.49% | A |
| Net Profit YoY | -2.39% | C |
| Total Assets YoY | 6.06% | C |
| Net Assets YoY | -14.93% | E |
| Cash Flow Margin | 84.01% | C |
| OCF YoY | 88.49% | A |
| Turnover | 0.28 | D |
| Gearing Ratio | 469.17% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - VolitionRx Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "88.49%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-2.39%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-0.62",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "19730914.38",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2466075.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "82.34%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-997.46%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "54.30%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "88.49%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-2.39%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.06%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-14.93%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "84.01%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "88.49%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.28",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "469.17%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.80 | 23/45 | - | - | - |
| PB | -0.62 | 40/45 | - | - | - |
| PS (TTM) | 8.00 | 37/45 | 52.05 | 28.36 | 18.42 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Essilor (ESLOY.US) | B | B | C | B | B | B |
| 02 | HOYA Corporation (HOCPY.US) | A | C | B | A | B | B |
| 03 | Align (ALGN.US) | B | C | B | B | C | B |
| 04 | Lantheus (LNTH.US) | A | C | B | C | C | B |
| 05 | Merit Medical (MMSI.US) | B | B | B | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-20T04:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 50% |
| Hold | 2 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.70 |
| Highest Target | 60.00 |
| Lowest Target | 16.83 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VNRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VNRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VNRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VNRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**